Bio Pharma Dive

MAY 16, 2024

The results, which showed Lilly’s drug was as effective at controlling blood sugar as standard injections, come as Novo Nordisk seeks approval for a competing once-weekly insulin.

Insulin 301

Insulin Drugs 301

STAT News

JUNE 20, 2025

Twelve people with type 1 diabetes who received an investigational off-the-shelf stem cell therapy were able to produce their own insulin and keep healthy blood glucose levels for at least one year, Vertex Pharmaceuticals said Friday. After 12 months, out of the 12 participants, 10 no longer needed to inject insulin.

Insulin 144

Insulin Medicine Research 144

Bio Pharma Dive

JULY 11, 2022

Gavin Newsom announced a $100 million budget to create a production facility and to develop affordable insulin products, saying the medicines’ high cost “epitomizes market failures.”

Insulin 240

Insulin Manufacturing Production Medicine 240

Pharmaceutical Technology

MAY 24, 2024

The US FDA's EMDAC is set to hold a meeting to assess the benefit-risk profile of Novo Nordisk's insulin icodec, to treat type 1 diabetes.

Insulin 246

Insulin 246

Medical Xpress

JUNE 16, 2025

Your brain makes insulin—the same insulin produced by your pancreas. The same insulin that is not produced in people with type 1 diabetes and the same insulin that does not work properly in people with type 2 diabetes.

Insulin 98

Insulin 98

Bio Pharma Dive

JULY 11, 2024

The FDA’s decision to turn back the drugmaker’s new insulin product narrows Novo’s lead in the U.S. over Eli Lilly, which has a similar diabetes treatment in late-stage testing.

Insulin 184

Insulin Production 184

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 9, 2022

The most effective way for people with diabetes to deliver insulin is also incredibly intrusive. Millions around the world must inject the crucial hormone underneath their skin several times a day to keep their glucose levels in balance.

Insulin 245

Insulin Hormones Scientist Clinical Trials 245

Pharmaceutical Technology

OCTOBER 12, 2022

Novo Nordisk has recently completed its six-part ONWARDS Phase III trial, as ONWARDS 5 reached its primary endpoint with Icodec demonstrating non-inferiority in reducing hemoglobin A1C (HbA1c) in patients with type 2 diabetes (T2D) at week 52 in comparison to once-daily basal insulin analogs. Patients had an overall baseline HbA1c of 8.9%

Insulin 182

Insulin Trials Marketing FDA Approval 182

NY Times

JUNE 20, 2025

Most in a small group of patients receiving a stem cell-based infusion no longer needed insulin, but the drug may not suit those with more manageable type 1 diabetes.

Insulin 112

Insulin Drugs Trials Clinical Trials 112

Medical Xpress

JUNE 16, 2025

Type 1 diabetes (T1D) is an autoimmune condition where the immune system destroys insulin-producing β-cells in the pancreas. Yet, not all patients lose insulin function at the same pace.

Insulin 59

Insulin Genetics 59

XTalks

FEBRUARY 18, 2025

The FDA has approved Sanofis Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar product for the treatment of diabetes. Merilog is a biosimilar to Novo Nordisks NovoLog, a widely used rapid-acting insulin aspart. Insulin, a hormone produced by the pancreas, allows glucose to enter cells for energy.

Insulin 59

Insulin FDA Approval Production Hormones 59

Pharma Times

OCTOBER 11, 2022

Therapy demonstrates significantly accelerated insulin absorption and early exposure

Insulin 164

Insulin Trials 164

Worldwide Clinical Trials

NOVEMBER 13, 2024

I was diagnosed with Type 1 diabetes, an autoimmune disease where the pancreas stops producing insulin, unlike Type 2 diabetes, where the body doesn’t produce enough or use it properly. There’s no cure and managing Type 1 requires multiple daily insulin injections (MDI) or an insulin pump.

Insulin 162

Insulin Doctor Doctors Clinical Trials 162

Bio Pharma Dive

NOVEMBER 18, 2022

Eli Lilly’s long-acting copycat drug, first approved in late 2021, now has a designation that will allow pharmacists to swap it for Sanofi’s Lantus.

Insulin 284

Insulin FDA Approval Drugs 284

Pharmaceutical Technology

MARCH 15, 2023

Novo Nordisk has announced plans to reduce the US wholesale acquisition cost (WAC), also known as the list price, of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes. Novo Nordisk also has various long-standing US affordability offerings for eligible people who are living with diabetes.

Insulin 147

Insulin Production Branding Marketing 147

Pharmaceutical Technology

MAY 26, 2023

Chronic disease tech company Convatec Group has partnered with Beta Bionics to manufacture the insulin delivery system iLet Bionic Pancrease. According to Beta Bionics, this is the only first and only automated insulin delivery system that carries 100% of doses and does not require carb counting.

Insulin 147

Insulin Manufacturing Pharmacy Marketing 147

Bio Pharma Dive

MARCH 14, 2023

Responding to policy changes and pressure over high drug costs, the pharma is reducing the sticker price of four branded diabetes medicines by up to 75%.

Insulin 293

Insulin Drugs Branding Medicine 293

Pharmaceutical Technology

SEPTEMBER 24, 2024

Coverage for its long-acting insulin, Levamir, dropped from 90% to about 35% when the company dropped its list price by 65%.

Insulin 312

Insulin 312

Pharmaceutical Technology

MARCH 22, 2024

The EMA CHMP has recommended marketing authorisation for Novo Nordisk's Awiqli for treating diabetes in adult patients.

Insulin 264

Insulin Marketing 264

Pharmaceutical Technology

AUGUST 2, 2024

Sanofi has announced a significant investment of €1.3bn ($1.4bn) to expand its insulin production capabilities in Frankfurt, Germany.

Insulin 130

Insulin Production 130

Bio Pharma Dive

JANUARY 13, 2023

The state filed suit Thursday against pharmacy benefit managers CVS Caremark, Express Scripts and OptumRx, alleging they worked with drugmakers to drive up the price of insulin.

Insulin 144

Insulin Pharmacy 144

Pharmaceutical Technology

SEPTEMBER 21, 2023

The licence grants Meitheal marketing rights for insulin aspart, lispro, and glargine following FDA approval.

Insulin 147

Insulin FDA Approval Marketing 147

NPR Health - Shots

MARCH 19, 2023

Under the $50 million deal, the state is partnering with drugmaker Civica to start making the new generic insulin later this year, Gov. Gavin Newsom said. Image credit: Damian Dovarganes/AP)

Insulin 144

Insulin 144

Bio Pharma Dive

JULY 29, 2021

An injectable insulin from Viatris has become the first-ever biosimilar product that can be directly substituted for a marketed biologic, a long-awaited decision that could put pricing pressure on other diabetes drugs.

FDA Approval 326

FDA Approval Insulin Production Marketing 326

Pharma Times

APRIL 29, 2022

InRange is the first worldwide multicentre RCT to compare second generation basal insulins

Insulin 139

Insulin 139

Pharmaceutical Technology

APRIL 18, 2024

At the ongoing Diabetes UK conference, experts highlighted the potential benefits and concerns surrounding weekly insulin candidates.

Insulin 130

Insulin 130

Fierce Pharma

APRIL 18, 2024

Novo Nordisk is receiving pushback from a trio of lawmakers over its decision to discontinue its long-acting insulin product Levemir, which was due for a steep discount at the start of the new year | Novo Nordisk is receiving pushback from a trio of lawmakers on its decision to discontinue its long-acting insulin product Levemir, which was due for (..)

Insulin 135

Insulin Production 135

Bio Pharma Dive

JULY 14, 2021

Rival Novo Nordisk has jumped ahead in developing an injectable drug that responds to changes in blood sugar. An acquisition of Protomer Therapeutics could help Lilly close the gap.

Insulin 293

Insulin Development Drugs 293

BioPharma Reporter

MAY 5, 2022

Oramed Pharmaceuticals announced this week that it has enrolled 100% of the patients in the worldâs first Phase 3 study of oral insulin under FDA approved protocols.

Insulin 127

Insulin Clinical Trials Clinical Trials FDA Approval 127

Bio Pharma Dive

MARCH 22, 2023

The companies will collaborate to identify compounds that could treat insulin resistance by targeting shape-shifting cellular droplets known as biomolecular condensates.

Insulin 301

Insulin Drugs 301

Pharmaceutical Technology

SEPTEMBER 10, 2024

Data from the two Phase III trials showed that efsitora induced HbA1C reductions similar to daily insulin in both type 1 and 2 diabetes.

Insulin 130

Insulin Trials 130

XTalks

NOVEMBER 4, 2024

Cure Research: Moving Toward an Insulin-Free Future JDRF is focused on funding research that is accelerating the development of new treatments for people with T1D — for all ages and stages. “Our before people need insulin therapy), so that it’s possible to intervene with therapies that can stop clinical disease before it starts.”

Insulin 108

Insulin Research Medicine Doctor 108

Bio Pharma Dive

FEBRUARY 8, 2023

In a State of the Union address, Biden threatened to veto any efforts to repeal the legislation and chastised drugmakers for the current costs of insulin.

Insulin 144

Insulin Drugs 144

Pharmaceutical Technology

SEPTEMBER 10, 2024

Data from the two Phase III trials showed that efsitora induced HbA1C reductions similar to daily insulin in both type 1 and 2 diabetes.

Insulin 130

Insulin Trials 130

pharmaphorum

JULY 11, 2024

FDA rejects Novo Nordisk’s once-weekly basal insulin for people with diabetes, which would reduce the number of injections needed

Insulin 111

Insulin 111

Bio Pharma Dive

MARCH 27, 2023

Vertex will license CRISPR technology to develop insulin-producing islet cells that are more resistant to immune rejection, adding to other efforts directed at Type 1 diabetes.

Gene Editing 293

Gene Editing Insulin Gene Licensing 293

Pharmaceutical Technology

JANUARY 10, 2023

In addition, market growth will be driven by dapagliflozin (Farxiga) in the SGLT-2I space, and novel GLP-1/GIP Mounjaro (tirzepatide), biosimilar/interchangeable insulins such as insulin lispro and insulin glargine (Basaglar), and the launch of once-weekly insulins icodec and Icosema, forecast for 2024 launch.

Insulin 130

Insulin Marketing Sales Compliance 130